D. T. Souza Gabriel

D. T. Souza Gabriel

Auto-generated profile, based on publicly available information

D. T. Souza Gabriel

Ilum School of Science, Brazilian Center for Research in Energy and Materials (CNPEM)

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
LMLetícia Marchese
Letícia Marchese
AEAmanda G. Eufrasio
Amanda G. Eufrasio
GSGabriel T. D. Souza
Gabriel T. D. Souza
MCMichelle F. Catelli
Michelle F. Catelli
ACArtur Cordeiro
Artur Cordeiro
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD + . Biochemical IC 50 assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC 50 (0.4 µM), outperforming benznidazole (EC 50 = 3.0 µM) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.

7 August 2025 in bioRxiv
Verified
Preprint
Open access
ÁLÁngel Eduardo Lobo-Rojas
Ángel Eduardo Lobo-Rojas
MLMarchese Letícia
Marchese Letícia
GAG. Eufrásio Amanda
G. Eufrásio Amanda
DGD. T. Souza Gabriel
D. T. Souza Gabriel
FMF. Catelli Michelle
F. Catelli Michelle
ACArtur Cordeiro
Artur Cordeiro
Chagas disease, caused by Trypanosoma cruzi , remains a leading cause of heart failure in Latin America, with current treatments limited to acute-phase efficacy, significant toxicity, and emerging resistance. Inosine monophosphate dehydrogenase (IMPDH) is an essential enzyme in guanine nucleotide salvage pathway and represents a promising alternative target. Here, we combined computational screening, biochemical and cell-based phenotypic assays that support T. cruzi IMPDH ( Tc IMPDH) as a druggable target and identify repurposing opportunities among clinical-stage inhibitors. Using Tanimoto similarity scoring against the library of 222 Chagas Box compounds, we identified TCMDC-143376 as uniquely similar to the clinical IMPDH inhibitors Merimepodib and AVN-944. Phylogenetic analysis and multiple sequence alignment confirmed conservation of both catalytic and allosteric residues—drawn from T. foetus and T. brucei structures—within Tc IMPDH. Recombinant Tc IMPDH kinetics revealed Michaelis constants of 155 µM for IMP and 292 µM for NAD⁺. Biochemical IC₅ ₀ assays showed submicromolar inhibition by AVN-944 (0.20 µM), (S)-Merimepodib (0.21 µM), and (R)-Merimepodib (0.37 µM). In H9c2 cardiomyoblasts infected with intracellular amastigotes, AVN-944 achieved the lowest EC₅ ₀ (0.4 µM) and highest selectivity index (SI > 100), outperforming benznidazole (EC₅ ₀ = 3.0 µM; SI = 13.4) and other inhibitors. Our findings support Tc IMPDH as a promising alternative drug target for Chagas disease and position AVN-944 as a compelling candidate to evaluate this therapeutic strategy in animal models.